Comment on "Apixaban vs. aspirin for stroke prevention in people with subclinical atrial fibrillation and a history of stroke or transient ischemic attack: subgroup analysis of the ARTESiA randomized controlled trial". (2025). Bleeding, Thrombosis and Vascular Biology, 4(2). https://doi.org/10.4081/btvb.2025.179